Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
OwnerArturo Solis Herrerainventor
Life of this patent
Estimating the term…
Abstract
Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.
Claims20
A method of treating a condition of a nasal or paranasal mucous membrane in a subject in need thereof, the method comprising administering to the nasal or paranasal mucous membrane of the subject a therapeutically effective amount of a pharmaceutical composition comprising a nicotinic acetylcholine receptor (nAChR) agonist selected from the group consisting of (S)-(1-methyl-2-pyrrolidinyl)-pyridine, (R)-(1-methyl-2-pyrrolidinyl)-pyridine, or a mixture thereof, or a pharmaceutically acceptable salt, analog, or precursor thereof and at least one pharmaceutically acceptable diluent, excipient, or carrier, wherein the condition of the nasal or paranasal mucous membrane is selected from the group consisting of rhinitis;
- allergic rhinitis;
- acute rhinitis;
- atrophic rhinitis;
- vasomotor rhinitis;
- chronic or recurrent sinusitis;
- an inflammation;
- a chronic inflammatory disease;
- an acute inflammatory disease;
- hemorrhages;
- minor bleeding;
- a chronic degenerative disease;
- an acute degenerative disease;
- edema of the mucous membranes;
- edema of one or more turbinates;
- postnasal drainage;
- facial pressure and pain;
- headaches;
- dripping of mucous membrane secretions down the throat;
- post nasal drip;
- abnormal taste sensations;
- feeling of dryness in the upper respiratory tract;
- drowsiness;
- nasal irritation;
- a loss of the sense of smell;
- burning sensations within the nose;
- ear or hearing issues;
- itchy nose;
- itchy eyes;
- sneezing;
- snoring;
- sleep apnea;
- asthma;
- nasal polyps (nasal polyposis);
- and exposure to environmental irritants or allergens.
A method of treating nasal hemorrhages (“nose bleeds”) in a human subject in need thereof, the method comprising nasally administering to the nasal or paranasal mucous membrane of the subject a therapeutically effective amount of an aqueous pharmaceutical composition comprising about 0.1 mg/ml to 2.0 mg/ml of (S)-(1-methyl-2-pyrrolidinyl)-pyridine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable diluent, excipient, or carrier, wherein the condition is.
A pharmaceutical composition comprising:
- a. (S)-(1-methyl-2-pyrrolidinyl)-pyridine or a pharmaceutically acceptable salt thereof at a concentration of about 0.1 mg/ml to 2 mg/ml;
- and
- b. a diluent, an excipient or a carrier suitable for a nasal administration comprising methylcellulose at a concentration of 0.5% by weight to 1% by weight based on a total weight of the composition;
- and salicylic acid at a concentration of about 0.5 mg/ml.
Dependencies are inferred from the claim text.